Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Biomarker Testing to Optimize NSCLC Care: Multidisciplinary Perspectives
  • CME

Matthew Gubens, MD, MS
Craig Mackinnon, MD, PhD
Released: July 6, 2022

Biomarker-Driven Neoadjuvant/Adjuvant Treatment in Early-Stage NSCLC

Moving Targeted Therapy and Immunotherapy Earlier in the Disease Course

Craig Mackinnon, MD, PhD:
Historically, biomarker testing was primarily performed on tumors from patients with advanced NSCLC. However, it is becoming increasingly evident that there is a role for biomarker testing in patients with early‑stage NSCLC.

Phase III IMpower010 Trial: Adjuvant Atezolizumab vs BSC in Resected Stage 1B-IIIA NSCLC After Adjuvant CT

Craig Mackinnon, MD, PhD:
The phase III IMpower010 trial demonstrated that adjuvant atezolizumab after adjuvant chemotherapy prolonged DFS compared with best supportive care after adjuvant chemotherapy in patients with early-stage NSCLC whose tumors expressed a PD-L1 level of ≥1% (HR: 0.66; 95% CI: 0.50-0.88; P = .004).53,54 The greatest DFS benefit with adjuvant atezolizumab was observed in patients with a high PD-L1 expression level of ≥50% (HR: 0.43; 95% CI: 0.27-0.68). There was no DFS benefit with adjuvant atezolizumab after adjuvant chemotherapy compared with best supportive care among patients with resected early-stage NSCLC with a PD-L1 expression level of <1% (HR: 0.97; 95% CI: 0.72-1.31). Based on these results, the FDA approved adjuvant atezolizumab following resection and platinum-based chemotherapy for the treatment of patients with stage II-IIIA NSCLC whose tumors express PD-L1 on ≥1% of tumor cells. So, there is a role for PD-L1 testing in early‑stage NSCLC. 

Phase III ADAURA Trial: Adjuvant Osimertinib for Early-Stage EGFR-Mutated NSCLC

Craig Mackinnon, MD, PhD:
The phase III ADAURA trial evaluated adjuvant osimertinib vs placebo in patients with completely resected EGFR mutation–positive stage IB-IIIA NSCLC. The trial demonstrated a significantly longer DFS among patients who received adjuvant osimertinib compared with placebo.55 The median DFS was not reached with adjuvant osimertinib vs 27.5 months with placebo (HR: 0.20; 99.12% CI: 0.14-0.30; P <.001). Based on the results of the ADAURA trial, the FDA approved osimertinib as adjuvant therapy following tumor resection in patients with NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations.

Provided by Clinical Care Options, LLC in partnership with the Association for Molecular Pathology

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

In partnership with
Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Genentech
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lilly
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings